Phase I Study of Decitabine Alone or in Combination With Valproic Acid in Acute Myeloid Leukemia

Abstract

Low-dose decitabine was safe and showed encouraging clinical and biologic activity in AML, but the addition of VA led to encephalopathy at relatively low doses. On the basis of these results, additional studies of decitabine (20 mg/m(2)/d for 10 days) alone or with an alternative deacetylating agent are warranted.